727 related articles for article (PubMed ID: 15700490)
1. [Nebivolol, a third generation beta blocker: the modern treatment of hypertension. Results of a multicentric observational study].
von Fallois J; Faülhaber HD
Fortschr Med Orig; 2000 Jul; 118 Suppl 2():77-82. PubMed ID: 15700490
[TBL] [Abstract][Full Text] [Related]
2. [Nebivolol, a beta blocker of the 3rd generation: modern therapy of arterial hypertension. Results of a multicenter observation study].
von Fallois J; Faulhaber HD
Praxis (Bern 1994); 2001 Mar; 90(11):435-41. PubMed ID: 11293936
[TBL] [Abstract][Full Text] [Related]
3. Nebivolol: a third-generation beta-blocker for hypertension.
Cheng JW
Clin Ther; 2009 Mar; 31(3):447-62. PubMed ID: 19393838
[TBL] [Abstract][Full Text] [Related]
4. Nebivolol in hypertension: a double-blind placebo-controlled multicenter study assessing its antihypertensive efficacy and impact on quality of life.
Van Bortel LM; Breed JG; Joosten J; Kragten JA; Lustermans FA; Mooij JM
J Cardiovasc Pharmacol; 1993 Jun; 21(6):856-62. PubMed ID: 7687708
[TBL] [Abstract][Full Text] [Related]
5. EVOLVE (nebivolol evaluation for efficacy and safety in the treatment of hypertension) postmarketing surveillance study.
Faruqui AA
J Indian Med Assoc; 2007 May; 105(5):272, 274, 276-7. PubMed ID: 17915798
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of nebivolol and valsartan on BP reduction and sleep apnoea activity in patients with essential hypertension and OSA.
Heitmann J; Greulich T; Reinke C; Koehler U; Vogelmeier C; Becker HF; Schmidt AC; Canisius S
Curr Med Res Opin; 2010 Aug; 26(8):1925-32. PubMed ID: 20560730
[TBL] [Abstract][Full Text] [Related]
7. Nationwide efficacy-safety study of nebivolol in mildly hypertensive patients.
Cleophas TJ; Agrawal R; Lichtenthal A; Mäkel W; Fici F
Am J Ther; 2006; 13(3):192-7. PubMed ID: 16772759
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial.
Grassi G; Trevano FQ; Facchini A; Toutouzas T; Chanu B; Mancia G
Blood Press Suppl; 2003 Dec; 2():35-40. PubMed ID: 14761075
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Nebivolol monotherapy versus Nebivolol in combination with other antihypertensive therapies for the treatment of hypertension.
Papademetriou V
Am J Cardiol; 2009 Jan; 103(2):273-8. PubMed ID: 19121451
[TBL] [Abstract][Full Text] [Related]
10. The role of the new beta-blockers in treating cardiovascular disease.
Weber MA
Am J Hypertens; 2005 Dec; 18(12 Pt 2):169S-176S. PubMed ID: 16373195
[TBL] [Abstract][Full Text] [Related]
11. Beta-blockers in the management of hypertension: focus on nebivolol.
Wojciechowski D; Papademetriou V
Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):471-9. PubMed ID: 18402537
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of nebivolol: does age matter? A retrospective analysis of three randomized, placebo-controlled trials in stage I-II hypertension.
Germino FW; Lin Y; Pejović V; Bowen L
Ther Adv Cardiovasc Dis; 2012 Oct; 6(5):185-99. PubMed ID: 23008339
[TBL] [Abstract][Full Text] [Related]
13. Effect of nebivolol and metoprolol treatments on serum asymmetric dimethylarginine levels in hypertensive patients with type 2 diabetes mellitus.
Oğuz A; Uzunlulu M; Yorulmaz E; Yalçin Y; Hekim N; Fici F
Anadolu Kardiyol Derg; 2007 Dec; 7(4):383-7. PubMed ID: 18065333
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
[TBL] [Abstract][Full Text] [Related]
15. Nebivolol/hydrochlorothiazide (HCTZ) combination in patients with essential hypertension: a pooled analysis from five non-interventional studies with a focus on diabetic and elderly patients.
Malacco E
Eur Rev Med Pharmacol Sci; 2010 May; 14(5):427-34. PubMed ID: 20556921
[TBL] [Abstract][Full Text] [Related]
16. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial.
Weiss RJ; Stapff M; Lin Y
Am J Cardiovasc Drugs; 2013 Apr; 13(2):129-40. PubMed ID: 23519546
[TBL] [Abstract][Full Text] [Related]
17. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension.
Lefebvre J; Poirier L; Poirier P; Turgeon J; Lacourciere Y
Br J Clin Pharmacol; 2007 May; 63(5):575-82. PubMed ID: 17094780
[TBL] [Abstract][Full Text] [Related]
18. Effect of treatment with nebivolol on parameters of oxidative stress in type 2 diabetics with mild to moderate hypertension.
Peter P; Martin U; Sharma A; Dunne F
J Clin Pharm Ther; 2006 Apr; 31(2):153-9. PubMed ID: 16635049
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of nebivolol in stage I-II hypertension: a pooled analysis of data from three randomized, placebo-controlled monotherapy trials.
Weiss RJ; Saunders E; Greathouse M
Clin Ther; 2011 Sep; 33(9):1150-61. PubMed ID: 21864908
[TBL] [Abstract][Full Text] [Related]
20. Impact of beta-blockers on sleep in patients with mild hypertension: a randomized trial between nebivolol and metoprolol.
Yilmaz MB; Erdem A; Yalta K; Turgut OO; Yilmaz A; Tandogan I
Adv Ther; 2008 Sep; 25(9):871-83. PubMed ID: 18758699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
